| Allergic conjunctivitis affects up to 40% of the general population1, and it is linked to a reduction in patients' quality of life. Allergens can be seasonal (like pollen) or perennial (like dust mites and pet dander), but allergic conjunctivitis symptoms include ocular irritation, tearing, burning, stinging, photophobia, redness, conjunctival swelling, and nasal problems. Allergic conjunctivitis is produced by an allergic reaction to an allergen that binds to immunoglobulin E on the surface of mast cells, resulting in inflammation. Mast cell activation and subsequent cellular release of histamine, tryptase, prostaglandins, and leukotrienes, which are responsible for the early phase of the allergic response, are induced by this binding (20-30 minutes after exposure). The aim of this research was to see how effective and safe a dexamethasone intracanalicular insert was at treating allergic conjunctivitis. The dexamethasone insert is used to alleviate itching caused by allergic conjunctivitis in the short term. Patients cannot abuse this insert because it is supplied by a physician and the dexamethasone is released for up to 30 days. The hydrogel implant biodegrades fully without the need for removal over time. Patients will need to be re-evaluated by the clinician if they require retreatment during the course of their diseaseddd |
